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1. Introduction
  
 The type 2 diabetes mellitus (T2DM) is a type 
of diabetes mellitus with the highest number of 
patients, covering 90-95% of the total diabetes 
mellitus case in the world. (American Diabetes 
Association 2012; Olokoba et al. 2012). This chronic 
metabolic disease is characterized by high blood 
sugar levels (hyperglycemia) caused by insulin 
resistance (reduction of insulin secretion or insulin 
function) (Weyer et al. 1999). The insulin secretion 
in the body occurs through various mechanisms, one 
of them depends on the role of incretin hormone. 
The Incretin hormone itself is a gut hormone that 
can stimulate insulin secretion in the body. One of 
incretin hormone that has a significant role in insulin 
secretion is GLP-1.
 Protein GLP-1 (Glucagon-like peptide 1) is 
an incretin hormone that mainly produced in 
enteroendocrine L cells of the gut shortly after 
eating or increasing glucose in the blood (Doyle 
and Egan 2007). This protein stimulates insulin 
secretion in the body by activating the GLP-1R 
agonists in pancreatic β cells to encourage adenylyl 
cyclase activation and cAMP (cyclic Adenosine Mono 
Phosphate) generation. This cAMP production will 
activate PKA (Protein Kinase A) and EPAC (Exchange 
Proteins Activated by cAMP) that play an essential 
role in insulin secretion (Meloni et al. 2012). The 
GLP-1 performs critical functions in the body 
such as: stimulating the insulin secretion from the 
pancreatic β-cells, stimulating the biosynthesis of 
insulin and insulin sensitivity, increasing the β-cell 
proliferation and apoptosis protection, inhibiting the 
glucagon secretion, gastric emptying, and food intake 
(Drucker 2001; Li et al. 2010; Quoyer et al. 2010). 
Those specific functions make the GLP-1 protein as 
one alternative that can be applied in treating the 
T2DM and as primary therapy for metabolic diseases 
such as obesity (Ahrén and Ahren 2011; Mostafa et 
al. 2015; Anderberg et al. 2016). The GLP-1 protein 
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lifetime in the body is only about 2 minutes before 
rapidly deactivated by an enzyme called DPP IV 
(Dipeptidyl peptidase 1V) (Baggio and Drucker 2007). 
Research on T2DM treatment is currently focused on 
increasing the activity of GLP-1R by developing GLP-
1 analog hormone or developing the DPP-IV inhibitor 
to maintain the amount of GLP-1 in the body. Some 
GLP-1 analogs such as exenatide and liraglutide have 
been found with longer-acting effects and considered 
more potent than GLP-1 wild-type (Briones and 
Bajaj 2006; Vilsbøll et al. 2008). Those analogs have 
similar amino acid structures with GLP-1 protein 
and interact with GLP-1R receptors (De Maturana et 
al. 2003; Russell-Jones 2009; McClean et al. 2011). 
The success of these two analogs in T2DM treatment 
provides an excellent opportunity to develop other 
analogs with better performance and stability.
 Study on protein modifications (or protein 
engineering) to improve the protein function and 
stability continues to be a significant interest topic 
in drug design, biotechnology, and food industries 
(Bai et al. 2016). This effort is mainly focused 
on the optimizing the expression, purification, 
modification, formulation, storage and structural 
studies of proteins (Deller et al. 2016). For the drug 
design field, the binding (docking) stability of ligand 
to the receptor are significant especially when 
we try to create a new design of protein agonist 
drugs. The stability and functionality of proteins 
depend on many factors, such as the electrostatic 
interactions, structural flexibility and also the amino 
acid (residue) sequence of the proteins (Jelesarov 
and Karshikoff 2009). Replacing one amino acid 
with the other (the point mutation method) could 
lead to the stabilization or destabilization of the 
whole structure and the functionality of the proteins 
(Jonson and Petersen 2001; Pikkemaat et al. 2002). 
The computational approach on the protein-protein 
interaction via molecular dynamics simulations and 
docking method might help us in designing new 
protein agonist drugs which further can be tested by 
in vivo and in vitro (wet experiments) methods.
 This paper is aimed to design and evaluate the 
performance of GLP-1 mutants using computational 
approach, the molecular dynamics simulation, and 
protein-protein docking simulation. The protein-
protein docking of GLP-1 ligand and GLP-1R receptor 
were performed to simulate the binding between 
those two proteins. The molecular dynamics 
simulation of those docked structures of GLP-1 and 
GLP-1R receptor was used to identify the essential 
salt-bridge pairs which always occurred in the 
simulation and play crucial roles in maintaining the 
stability of the ligand-receptor binding. Once the 
salt-bridge couple recognized, the point mutations 
conducted on ligand’s amino acid to design some 
GLP-1’s mutants. The molecular dynamics simulation 
then performed on the mutants to find the most 
stable mutant which has better binding stability 
and the docked structure integrity. The stability 
interaction of this GLP-1 mutant was also compared 
to the available peptide agonist drugs (GLP-1 
analogs) available in the market, such as exenatide, 
and liraglutide.
2. Materials and Methods
 The initial structure of the protein was 
downloaded from protein data bank (www.rcsb.org) 
with the PDB code name 1D0R for GLP-1 (Chang et 
al. 2001), 3C59 for GLP-1R (Runge et al. 2008), 1JRJ 
for exenatide (Neidigh et al. 2001), and 4APD for 
liraglutide (Worldwide PDB 2014). The GLP-1 protein 
consists of 30 residues, during exenatide 39 residues, 
and liraglutide 31 residues. The wild-type sequence 
of the GLP-1 peptide is shown in Table 1, and the 
site chosen for mutational study is highlighted. The 
residue sequence of downloaded GLP-1R protein was 
started from 20 to 131, but to simplify the simulation 
and analysis, we renumbered the residue to begin 
from 50 to 152. The protein structures were prepared 
using VMD 1.9 (Visual Molecular Dynamics) 
program (Humphrey et al. 1996) before running the 
molecular dynamics simulations. Preparation of 
protein structure consists of removing ligands and 
water molecules, setting the center of coordinate, 
creating the topological files, creating the water box 
(±14Å from the edge of protein structure in the x-y-z 
coordinates), neutralizing the molecules by adding 
NaCl ions (0.15 mol/l). A series of minimization 
process (for 10 ns) then performed to put the protein 
Table 1. The amino acid sequence of a GLP-1 peptide. The 
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structure in the minimum energy state (the most 
stable conformation) before proceeding to the next 
step, i.e., protein-protein docking simulation.
 The protein-protein docking simulations were 
performed between the receptor protein GLP-1R and 
ligand proteins (GLP-1, exenatide, and liraglutide) 
using an online server ZDOCK (Chen et al. 2003; 
Pierce et al. 2014). For each docking simulation, the 
Z-dock server will produce ten binding modes. Based 
on the Z-dock scoring function the first compulsory 
mode (complex.1.pdb) is taken as best docked 
structure (as seen in Figure 1) and will be used for 
molecular dynamics simulation.
 The docked structures produced by Z-DOCK then 
simulated again using NAMD (Not Just Another 
Molecular Dynamics) version 2.9 software (Phillips et 
al. 2005) to check the structural integrity and identify 
factors responsible for the stability of ligand-receptor 
interactions. The molecular dynamics simulation 
were comprised of minimization (10 ns), heating and 
equilibration (5 ns, 310 K), and the production run of 
molecular dynamics simulation (50 ns) with 2 fs time 
step and SHAKE constraint (Ryckaert et al. 1977). For 
the accuracy, the simulation of the docked structure 
of GLP-1 wild-type and GLP-1R was run three times. 
The first run was done with the initial structure came 
from the Z-Dock result (complex.1.pdb). The second 
run used the initial structure came from the 10 ns 
frame of the first simulation, while the third run used 
the initial structure came from the 20 ns frame of 
the first simulation. All simulations were performed 
using the same parameters system and conditions.
 To identify the factors or residues responsible for 
the binding stability of the ligand-receptor structure, 
some parameters must be analyzed such as the 
RMSD (root mean square deviation), SASA (solvent 
accessible surface area), radius of gyration, RMSF 
(root mean square fluctuation), and the binding 
energy between ligands and receptor. Based on those 
results, we can determine the essential residue (or 
residues) that maintain the interaction stability. 
Since we can only mutate ligand (modify ligand) 
and not the receptor, so the residue that we analyze 
should be in ligand structure. Once the residue was 
identified, then we can evaluate the role of this 
residue by making point mutations. The free energy 
perturbation (FEP) approach was used to calculate 
the effect of mutation to the energetic stability of the 
docked structure by using a dual topology paradigm 
under aqua and vacuum (waterless condition) (Henin 
et al. 2017), as illustrated in Figure 2.
Figure 1. The docked structures of the ligand-receptor 
interaction produced by Z-DOCK server. The GLP-
1R receptor docked with (a) GLP-1 (b) Exenatide, 
and (c) Liraglutide. The blue color represents the 
receptor protein, and the red color represents 
ligand protein. The left panels (images) are in 
the secondary structure representation, while 














Figure 2. Thermodynamics cycle of solvent-free energy 
changes
94                                                                                                                                                           Sumaryada T et al.
HAYATI J Biosci                                                                                                                                                                     95
Vol. 28 No. 1, January 2021
 In the FEP approach, the energy of each process 
above was defined as:
3. Results
The molecular dynamics simulation of the docked 
structure of the GLP-1 wild-type and the GLP-1R receptor 
was run three times for 50 ns each, and at 310 K. The 
results, as seen in Figure 3, indicate that those three runs 
of simulation did not produce a drastic conformational 
change as shown by the relatively low value of RMSD 
of the backbone of protein-protein docking.
The salt-bridge interactions between GLP-1 and GLP-
1R were tabulated in Table 2 and become the selection 
basis for protein mutation. Two salt-bridges, Lys20-
Glu89, and Glu21-Arg142 have been identified as the 
most frequent salt-bridge pairs that appeared during 
simulations. The dynamics of those mutations in terms 
of electrostatic energy and the interaction distance of 
Lys20-Glu89 and Glu21-Arg142 mutants were shown 
in Figure 4. The degree of the mutation of GLP-1 can be 
expressed in terms of solvation free energy changes as 
shown in Figure 5. Lambda = 0 denotes that the protein 
structure is entirely in the wild-type form, while lambda 
= 1 indicates that the protein structure is altogether 
in the mutant form.
The binding stability of GLP-1’s mutants and GLP-1R 
at physiological temperature (310 K) in terms of some 
molecular dynamics structural’s parameters (RMSD, Rg, 
SASA, and RMSF) is shown in Figure 6. The dynamics 
of the tertiary structures of the mutant’s complexes 
are shown in Figure 7. In that figure, the attachment 
and detachment of GLP-1 and its mutants with GLP-1R 
during molecular dynamics simulation can be tracked 
to evaluate the structural integrity of the complexes. 
As seen in Figure 7, the best mutant that maintains the 
structural integrity of the ligand-receptor complex is 
Lys20His. The binding of GLP-1 wild-type, Lys20His 
mutant, exenatide, and liraglutide to GLP-1R then 
compared in Figure 8. The binding stability as seen in 
Figure 8 shows the evolution of the structural parameter 
of the complexes, such as RMSD, Rg, SASA, and RMSF. 
In terms of energetical parameters, the binding affinity 
where, 
  : the energy required for mutations in a 
vacuum (kcal/mol)
  : the energy required for mutations in a 
vacuum (kcal/mol)
  : the energy required to dissolve the wild-
type (kcal/mol)
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 For the calculation of the binding energy of ligand-
protein with receptor-protein, the MM/PBSA (Molecular 
Mechanics Poisson Boltzmann Surface Area) and MM/
GBSA (Molecular Mechanics Generalized Born Surface 
Area) methods within the AMBER program was used 
(Hou et al. 2011). This approach follows some equations 
below:
where, 
  : the total gas phase mechanical energy of 
the molecular system which includes the 
internal energy (energy binding, angle, and 
dihedral) van der Walls (           ) and the 
electrostatic interaction ( ) in the 
unit of kcal/mol
  : the free energy of ligand bonds removal, 
determined from Poisson Boltzmann (PB)/
Generalized Born (GB) and SASA calculations, 
in the unit of kcal/mol
  : the product of temperature (at 310K) and 
the solubility entropy arising from the change 
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∆E electrostatic 













Run 1 Run 2 Run 3
Figure 3. The RMSD value of the docked structure of GLP-1 
and GLP-1R during simulation of each run
Table 2. Salt-bridge pairs between GLP-1 and GLP-1R 
receptor appears during each simulation

























































































Figure 4. (a) The electrostatic energy, and (b) the interaction distance of Lys20-Glu89 salt-bridge pair, while (c) the 
electrostatic energy, and (d) the interaction distance of Glu21-Arg142 salt-bridge pair













Figure 5. The changes of solvation free energy of GLP-1 
mutant candidates. Lambda = 0 denotes that 
the protein structure is entirely in the wild-type 
form, while lambda = 1 indicates that the protein 
structure is altogether in the mutant form
-5
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Lys20Ala Lys20Serof those complexes was compared using MM/PBSA 
(relative binding energy) and MM/GBSA method and 
tabulated in Table 3. 































































Residue0 10 20 30 40 50
Time (ns)
Lys20Arg Lys20Ala Lys20Ser Lys20Gly Lys20His
Figure 6. Stability analysis of GLP-1 mutants during 50 ns simulation based on (a) RMSD values, (b) SASA, (c) Radius of 
gyration, and (d) RMSF
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Figure 7. The binding evolution of Wild-type GLP-1, GLP-1 mutants, and GLP-1R receptor during the 50 ns simulation. 
Notice that Lys20His remains stable (docked) as compared to other mutants which detach from the receptor 
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Wild-type Lys20His mutant Exenantide Liraglutide
Figure 8. The stability analysis of mutant Lys20His as compared to the wild-type GLP-1, exenatide, and liraglutide during 
50 ns molecular dynamics simulation
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4. Discussion
 The molecular dynamics simulation of the docked 
structure of the wild-type GLP-1 and the GLP-1R 
receptor was run three times for 50 ns each, and at 
310 K. The results have shown that those three runs of 
simulation did not produce a drastic conformational 
change (the docked structures are stable in each run). 
The stability of the docked structures is maintained 
during the simulation as demonstrated by the RMSD 
value of the backbone of protein-protein docking 
(Maiorov and Crippen 1994) which range from 2.47 
to 6.1 Å.
 The salt-bridge interactions between GLP-1 
and GLP-1R binding were analyzed by identifying 
the positive and negative polar residue pairs that 
interact actively during the simulations (Winters 
and Day 2002). Salt-bridge interaction contributes 
essential roles in the flexibility and the stability of 
the protein structures, and also the balance of the 
docked structures of the protein-protein interaction 
(Horovitz et al. 1990; Xu et al. 1997; Karshikoff and 
Jelesarov 2008; Gribenko et al. 2009; Jelesarov and 
Karshikoff 2009). In Table 2, it was found that two 
active salt-bridges, Lys20-Glu89 and Glu21-Arg142, 
are found (existed) in each simulation and assumed 
as the essential salt-bridge pairs in maintaining the 
stability of the docked structures. These salt bridge 
pairs were further selected as the candidates for the 
point mutation. Recall that the salt-bridge pair Lys20-
Glu89 means the electrostatic interaction between 
Lys20 (in the GLP-1 ligand) and Glu89 (in the GLP-1R 
receptor). Since the mutation was designed for the 
ligand, so the candidate for mutation are Lys20 and 
Glu21 which further tested and selected based on the 
results of molecular dynamics simulation.
 The electrostatic energy of Lys20-Glu89 and 
Glu21-Arg142 salt-bridge pairs during simulation 
were shown in Figure 4. The electrostatic interaction 
reinforces the non-covalent interaction in the protein 
structure, as emphasized by this Ref (Kumar and 
Nussinov 2002). Based on the electrostatic energy 
analysis, Glu21-Arg142 has stronger interaction as 
compared to the Lys20-Glu89 salt-bridge pair. The 
electrostatic energy of the Glu21-Arg142 pair has 
a more negative value (-85.293±7.633 kcal/mol) 
and shorter backbone distance (8.005±0.948 Å.) as 
compared to Lys20-Glu89 which has less negative 
electrostatic energy (-13.269±12.669 kcal/mol) and 
a longer backbone distance (11.157±0.688 Å). The 
distance formed between two interacting residues 
influences the amount of electrostatic energy 
formed (Dominy et al. 2004; Maleki et al. 2013). The 
zero-value of electrostatic energy of the Lys20-Glu89 
pair corresponds to a longer distance of separation 
between those two residues which exceeds the cut-
off set up by the NAMD program (Ryckaert et al. 1977; 
Phillips et al. 2005).
 From the electrostatic energy, the salt-bridge 
pair of Lys20-Glu89 was the weakest among other 
salt-bridge pairs in the binding of GLP-1 and GLP-
1R complexes. Based on that result, we decided to 
make some point mutations of Lys20 residue to find 
the best replacement of that amino acid which could 
enhance the binding stability of the protein-protein 
docking. The Lys20 residue is a positive polar amino 
acid group, while its partner Glu89 is a negatively 
polar group. To analyze the effect of mutations 
on the binding stability, some residues must be 
selected from the same positive polar group such as 
Arginine and Histidine. The mutant candidates can 
also be chosen from the neutral polar group, such as 
Serine and Glycine, and nonpolar group like Alanine 
(Jonson and Petersen 2001; Wei et al. 2007). By 
using the popular convention for mutation symbol, 
the Lys20Arg means a point mutation by replacing 
Lysine with Arginine.
 From the five designed mutants (Lys20Arg, 
Lys20Ala, Lys20Ser, Lys20Gly, Lys20His), Lys20His 
turned out to have the most negative ∆∆Gsolv (∆∆Gsolv 
= -5.135 kcal/mol) as compared to other mutants 
(∆∆Gsolv = -0.5705 kcal/mol for Lys20Ala, ∆∆Gsolv 
= +5.342 kcal/mol for Lys20Gly, ∆∆Gsolv = +10.437 
kcal/mol for Lys20Ser and ∆∆Gsolv = +20.512 kcal/
mol for Lys20Arg). This implies that Lys20His is the 
best mutant candidate to be developed as a GLP-1R 
agonist.
Table 3. The binding affinity of GLP-1R receptor and the 
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 To evaluate the binding stability of GLP-1’s 
mutants with GLP-1R, the molecular dynamics 
simulation of those five mutants (Lys20Arg, Lys20Ala, 
Lys20Ser, Lys20Gly, Lys20His) were performed at 310 
K for 50 ns. In Figure 6, some molecular dynamics 
parameters such as RMSD, SASA (Solvent Accessible 
Surface Area indicates the area of protein's interior 
exposed by the solvent), Radius of gyration (the 
protein compactness), and RMSF (The Root Mean 
Square Fluctuation, or the flexibility of each residue) 
were shown as a function of simulation time. 
Based on the RMSD values, the binding of Lys20His 
mutant to its receptor was very stable as indicated 
by the minimum amount of RMSD which remained 
constant until the end of simulation at 50 ns. On the 
other hand, the other four mutants began to detach 
from the receptors at 34.57 ns for Lys20Gly, at 38.98 
ns for Lys20Arg, at 39.236 ns for Lys20Ala, and at 
42.704 ns for Lys20Ser as seen in Figure 7. The same 
situation can be found in the value of the radius of 
gyration. The value of the radius of gyration and 
RMSD of Lys20His mutant remained stable during the 
simulation, while the other four mutants underwent 
a quite drastic change (See Figure 6b). The SASA value 
of Lys20His mutant has a stable value ranging from 
8952 to 10073 Å2 (1121 Å2 area change), whereas the 
SASA value of other mutants has a more significant 
range and area change. For the Lys20Arg the SASA 
value ranging from 8829 to 11607 Å2 (2778 Å2 
area change), Lys20Ala ranging from 9050 to 11767 
Å2 (2717 Å2 area change), Lys20Ser ranging from 
8730 to 11337 Å2 (2607 Å2 area change) as seen in 
Figure 6c. The enlargement of the SASA area directly 
corresponds to the breaking of the salt-bridge pairs 
which in this case displayed the detachment process 
of the ligand from the receptor (Durham et al. 2009). 
The RMSF analysis showed that the Lys20His mutant 
has the most stable structures as compared to other 
mutants as demonstrated by the lower RMSF values 
(See Figure 6d).
 Figure 8 showed the docking (binding) stability of 
Lys20His GLP-1 mutant to GLP-1R as compared to the 
wild-type GLP-1 and the available peptide agonist 
drugs in the market, exenatide, and liraglutide during 
the 50 ns simulation. As shown in Figure 8, the 
Lys20His mutant showed good results (more stable 
binding) based on its lower RMSD, Radius of gyration 
and SASA values. The RMSF analysis also indicated 
that the replacement of Lysine-20 with Histidine 
maintained the compactness of the docked structures. 
The SASA value of Lys20His mutant was ranging from 
8951 to 10073 Å2 which was almost similar to the 
value of the wild-type that range from 8479 to 10200 
Å2. Comparing to other mutants, the replacement of 
Lysine-20 with Histidine did not change the SASA’s 
value too much and kept the docked structure in a 
stable state. The SASA value of Lys20His mutant 
was also lower than exenatide (9712-11151 Å2) and 
liraglutide (9040-10665 Å2). Overall based on those 
molecular dynamics parameters, we can assume that 
our designed mutant Lys20His has better binding 
stability as compared to other mutants and the 
available peptide agonist drugs on the market.
 To evaluate the binding affinity of Lys20His 
mutant, GLP-1 wild-type, exenatide, and liraglutide 
to the GLP-1R receptor, the binding energy calculation 
using the MM/PBSA and MM/GBSA methods were 
performed. The results of those methods were 
presented in Table 3. The binding affinity calculation 
was intended to describe and analyze the strength of 
protein-protein interaction (Hou et al. 2011; Beard et 
al. 2013). Based on the data in Table 3, the Lys20His 
mutant has stronger binding energy as compared to 
liraglutide. When Lys20His mutant was compared 
to wild-type GLP-1, it has a smaller standard 
deviation, both in MM/PBSA or MM/GBSA method. 
Those results suggest that replacing Lysine-20 with 
Histidine improves the docking stability of GLP-
1 with the GLP-1R receptor. The slight difference 
between the binding affinity of the Lys20His mutant 
with the wild-type GLP-1 and liraglutide reflects 
the similar energetic performance of this mutant as 
compared to the natural agent. The stronger binding 
affinity of exenatide as compared to Lys20His was 
expected due to a bigger size and more residues 
(39 residues in exenatide) involved in the protein-
protein interactions since the number of amino acids 
as we know significantly affects the calculation of 
the binding energy (Genheden and Ryde 2015; Duan 
et al. 2016).
 The replacement of Lysine-20 with Histidine 
has increased the binding stability as compared 
to other mutants and analogs as shown by its 
structural parameters (Figure 6) and energetical 
parameters (Table 3). The replacement of Lysine-20 
with Histidine also creates a stronger and flexible 
binding due to the nature of Histidine which can be 
in the interior or exterior of the protein and more 
comfortable to move proton (change from neutral 
to positively charged residue) as compared to Lysine 
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which prefers on the outside of protein and interact 
with other carboxy groups, anions or involved in salt-
bridge interaction. There are some efforts to increase 
the binding quality of GLP-1 and GLP-1R receptor, 
including these references (Green et al. 2003; Green 
et al. 2004; Dods and Donnelly 2016). According to 
(Dods and Donnelly 2016) who performed mutation 
on GLP-1R, the ligand-receptor binding mostly 
occurred between the N terminal domain (NTD) of 
GLP-1 peptides such as His1, Glu3, Ser 8, Asp9 and 
the cavity (pocket interaction) of GLP-1R, with a 
minority of GLP-1R amino acids interacts with the 
helical section of the GLP-1 (from Ala18 to Val27). 
Most of the effort in modifying GLP-1 have been 
focused on NTD to avoid the rapid destabilization of 
GLP-1 by dipeptidyl peptidase IV (DPP IV) enzyme, 
for example (Green et al. 2003) who performed 
mutation of Glu9 (in our GLP-1 structure, Glu3) with 
Proline, Phenyl, and Tyrosine. In this paper, we have 
demonstrated that the protein modification can be 
done in other section of GLP-1 by replacing Lys20 
with His20 and still produces better binding stability 
as compared to the wild-type of GLP-1.
5. Conclusion
 We have conducted a computational approach 
of protein-protein docking, molecular dynamics 
simulation, free energy perturbation, and molecular 
mechanics binding affinity calculation to design a 
stable GLP-1 ligand that has the strongest binding 
affinity to the GLP-1R receptor. Out of five mutant 
candidates (Lys20Arg, Lys20Ala, Lys20Ser, Lys20Gly, 
Lys20His), Lys20His has shown good interaction 
stability with GLP-1R receptor as indicated by some 
molecular dynamics parameters of RMSD, RMSF, the 
radius of gyration and SASA. The binding affinity 
calculation using MM/PBSA and MM/GBSA technique 
has also shown a strong binding affinity of Lys20His 
with the GLP-1R receptor. In summary, we have 
successfully designed a new mutant of GLP-1 incretin 
hormone which showed almost similar stability 
structurally and energetically to the wild-type GLP-
1 and a better balance as compared to the peptide 
agonist drugs available in the market, exenatide, and 
liraglutide.
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